Topic
1 story, newest first.
Investments in pharmaceutical companies on behalf of President Donald Trump reportedly increased substantially after his return to the White House. A report from congressional Democrats details a rise in stock holdings in firms that benefited from Medicare drug price negotiation exemptions.
